Marker Therapeutics appoints Juan Vera as CSO and COO effective Nov 12, 2021

Marker Therapeutics, Inc.

Juan Vera, former Chief Development Officer, appointed as Chief Scientific Officer and Chief Operating Officer.
Effective November 12, 2021; he continues as a board member through the 2022 annual meeting.
No family relationships or material interests in transactions require disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Juan Vera

Chief Scientific Officer and Chief Operating Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2021-11-12
Filed: November 15, 2021, 6:59 PM ET

On November 10, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Juan Vera, M.D., the Company’s then-current Chief Development Officer, to serve as the Company’s Chief Scientific Officer and Chief Operating Officer, effective as of November 12, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Juan Vera was appointed as Chief Scientific Officer and Chief Operating Officer at Marker Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer and Chief Operating Officer

Exact text from the filing

On November 10, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Juan Vera, M.D., the Company’s then-current Chief Development Officer, to serve as the Company’s Chief Scientific Officer and Chief Operating Officer, effective as of November 12, 2021.

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-138506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.